542 related articles for article (PubMed ID: 26222558)
41. An unusual presentation of diffuse tenosynovial giant cell tumour in the neck.
Pillai G; Nicolas M; Lwin K; Pezzella F; Gatter K
Histopathology; 2003 Oct; 43(4):393-6. PubMed ID: 14511259
[No Abstract] [Full Text] [Related]
42. Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes.
Al-Ibraheemi A; Ahrens WA; Fritchie K; Dong J; Oliveira AM; Balzer B; Folpe AL
Mod Pathol; 2019 Feb; 32(2):242-251. PubMed ID: 30206409
[TBL] [Abstract][Full Text] [Related]
43. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA; Weisser M; Jacob W; Jegg AM; Ries CH; Rüttinger D
J Immunother Cancer; 2017 Jul; 5(1):53. PubMed ID: 28716061
[TBL] [Abstract][Full Text] [Related]
44. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors.
Möller E; Mandahl N; Mertens F; Panagopoulos I
Genes Chromosomes Cancer; 2008 Jan; 47(1):21-5. PubMed ID: 17918257
[TBL] [Abstract][Full Text] [Related]
45. Tenosynovial giant cell tumor: case report and review.
Lucas DR
Arch Pathol Lab Med; 2012 Aug; 136(8):901-6. PubMed ID: 22849738
[TBL] [Abstract][Full Text] [Related]
46. PLX3397, a CSF1 receptor inhibitor, limits allotransplantation-induced vascular remodelling.
Almonte VM; Uriyanghai U; Egaña-Gorroño L; Parikh D; Oliveira-Paula GH; Zhang J; Jayakumar S; Riascos-Bernal DF; Sibinga NES
Cardiovasc Res; 2022 Sep; 118(12):2718-2731. PubMed ID: 34478521
[TBL] [Abstract][Full Text] [Related]
47. [Case report: Tenosynovial giant cell tumor arising from the knee joint].
Yildiz S; Cetinkol E
Tani Girisim Radyol; 2003 Mar; 9(1):81-3. PubMed ID: 14661299
[TBL] [Abstract][Full Text] [Related]
48. Diffuse-type tenosynovial giant cell tumor in association with neurofibromatosis type 1-Noonan syndrome: possibly more than a chance relationship.
Posligua L; McDonald DJ; Dehner LP
Am J Surg Pathol; 2006 Jun; 30(6):734-8. PubMed ID: 16723851
[TBL] [Abstract][Full Text] [Related]
49. Pexidartinib: First Approval.
Lamb YN
Drugs; 2019 Nov; 79(16):1805-1812. PubMed ID: 31602563
[TBL] [Abstract][Full Text] [Related]
50. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel
Mejbel H; Siegal GP; Wei S
Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489
[TBL] [Abstract][Full Text] [Related]
51. Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints.
Kim DE; Kim JM; Lee BS; Kim NK; Lee SH; Bin SI
Knee Surg Sports Traumatol Arthrosc; 2018 Nov; 26(11):3508-3514. PubMed ID: 29637236
[TBL] [Abstract][Full Text] [Related]
52. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
[TBL] [Abstract][Full Text] [Related]
53. Tenosynovial giant cell tumor in the cervico-thoracic junction.
Okutan O; Solaroglu I; Ozen O; Saygili B; Beskonakli E
Turk Neurosurg; 2012; 22(6):769-71. PubMed ID: 23208911
[TBL] [Abstract][Full Text] [Related]
54. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
[TBL] [Abstract][Full Text] [Related]
55. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis.
Fiocco U; Sfriso P; Lunardi F; Pagnin E; Oliviero F; Scagliori E; Cozzi L; Vezzù M; Molena B; Scanu A; Panziera C; Nardacchione R; Rubaltelli L; Dayer JM; Calabrese F; Punzi L
Autoimmun Rev; 2010 Sep; 9(11):780-4. PubMed ID: 20620241
[TBL] [Abstract][Full Text] [Related]
56. Soft tissue giant cell tumor of low malignant potential: a proposal for the reclassification of malignant giant cell tumor of soft parts.
Folpe AL; Morris RJ; Weiss SW
Mod Pathol; 1999 Sep; 12(9):894-902. PubMed ID: 10496598
[TBL] [Abstract][Full Text] [Related]
57. Multiple metastases from histologically benign intraarticular diffuse-type tenosynovial giant cell tumor: a case report.
Asano N; Yoshida A; Kobayashi E; Yamaguchi T; Kawai A
Hum Pathol; 2014 Nov; 45(11):2355-8. PubMed ID: 25130396
[TBL] [Abstract][Full Text] [Related]
58. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
[TBL] [Abstract][Full Text] [Related]
59. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H; de Sande MV
Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
[TBL] [Abstract][Full Text] [Related]
60. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Cassier PA; Italiano A; Gomez-Roca C; Le Tourneau C; Toulmonde M; D'Angelo SP; Weber K; Loirat D; Jacob W; Jegg AM; Michielin F; Christen R; Watson C; Cannarile M; Klaman I; Abiraj K; Ries CH; Weisser M; Rüttinger D; Blay JY; Delord JP
Eur J Cancer; 2020 Dec; 141():162-170. PubMed ID: 33161240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
